ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs INCYTE CORP (INCY)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ALNY | INCY |
|---|---|---|
| Sector | Health Care | Industrials |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $3.71B | $5.14B |
| Revenue growth (YoY) | ▲ 65.2% | ▲ 21.2% |
| Net income | $313.75M | $1.29B |
| Gross margin | 81.8% | 92.8% |
| Diluted EPS | $2.33 | $6.41 |
| Insider net (6 mo) | +15.8K sh • 2 sells • 0 buys | −61.3K sh • 16 sells • 0 buys |
| Institutional owners | 57 | 51 |
| Institutional value held | $30.04B | $12.84B |
| Next earnings (est.) | Around Feb 11, 2027 | Feb 9, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that develops therapeutics based on RNA interference (RNAi). Read more →
About INCYTE CORP (INCY)
Incyte is a global biopharmaceutical company that discovers, develops and commercializes proprietary therapeutics. Its global headquarters is in Wilmington, Delaware, where it conducts discovery, clinical development and commercial operations. Read more →
Source: SEC EDGAR.